These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 1640727)

  • 1. Cytogenetic effects on cells derived from patients with myelodysplastic syndromes during treatment with hemopoietic growth factors.
    Verhoef G; Van den Berghe H; Boogaerts M
    Leukemia; 1992 Aug; 6(8):766-9. PubMed ID: 1640727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of recombinant human granulocyte colony stimulating factor and granulocyte-monocyte colony stimulating factor on in vitro hemopoiesis in the myelodysplastic syndromes.
    Nagler A; Ginzton N; Negrin R; Bang D; Donlon T; Greenberg P
    Leukemia; 1990 Mar; 4(3):193-202. PubMed ID: 1690318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haemopoietic growth factors.
    Merchav S; Wagemaker G; Souza LM; Tatarsky I
    Leukemia; 1991 Apr; 5(4):340-6. PubMed ID: 1709245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Importance of GM-CSF for in vitro cytogenetic bone marrow analysis in patients with myelodysplastic syndrome].
    Karásková J; Holena O; Michalová K
    Cas Lek Cesk; 1997 Oct; 136(20):633-7. PubMed ID: 9490208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro study of erythropoiesis in patients with aplastic anemia and myelodysplastic syndromes: a possible tool for prospective determination of the clinical effectiveness of growth factors.
    Aoki A; Shibata A
    Hematol Pathol; 1992; 6(3):143-53. PubMed ID: 1429342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodysplastic syndromes: comparison between recombinant human granulocyte colony-stimulating factor (CSF) and granulocyte-monocyte CSF.
    Nagler A; Binet C; Mackichan ML; Negrin R; Bangs C; Donlon T; Greenberg P
    Blood; 1990 Oct; 76(7):1299-307. PubMed ID: 1698477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of in vivo treatment with rh GM-CSF on in vitro growth of haematopoietic progenitors in patients with myelodysplastic syndromes.
    Visani G; Tosi P; Finelli C; Gamberi B; Zauli G; Cenacchi A; Fogli M; Colombini R; Tura S
    Haematologica; 1992; 77(2):142-5. PubMed ID: 1383105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth of human hematopoietic colonies from patients with myelodysplastic syndromes in response to recombinant human granulocyte-macrophage colony-stimulating factor.
    Carlo-Stella C; Cazzola M; Bergamaschi G; Bernasconi P; Dezza L; Invernizzi R; Pedrazzoli P
    Leukemia; 1989 May; 3(5):363-6. PubMed ID: 2654496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C; Zahner J; Sayer HG
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro growth of myeloid and erythroid progenitor cells from myelodysplastic patients in response to recombinant human granulocyte-macrophage colony-stimulating factor.
    Mayani H; Baines P; Bowen DT; Jacobs A
    Leukemia; 1989 Jan; 3(1):29-32. PubMed ID: 2642575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered responses of purified blast cells from the myelodysplastic syndromes to colony-stimulating factors in vitro: comparison with normal blast cells.
    Tohyama K; Ueda T; Yoshida Y; Nakamura T
    Exp Hematol; 1994 Jul; 22(7):539-45. PubMed ID: 7516887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferative response of human acute myeloid leukemia cells and normal marrow enriched progenitor cells to human recombinant growth factors IL-3, GM-CSF and G-CSF alone and in combination.
    Lemoli RM; Gulati SC; Strife A; Lambek C; Perez A; Clarkson BD
    Leukemia; 1991 May; 5(5):386-91. PubMed ID: 1709711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mast cell growth factor (c-kit ligand) restores growth of multipotent progenitors in myelodysplastic syndrome.
    Glinsmann-Gibson B; Spier C; Baier M; Taetle R; Broudy VC; List AF
    Leukemia; 1994 May; 8(5):827-32. PubMed ID: 7514248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of haemopoietic growth factors in the treatment of myelodysplastic syndromes.
    Greenberg PL; Negrin R; Nagler A
    Cancer Surv; 1990; 9(1):199-212. PubMed ID: 2276114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential responses of myeloid progenitor cells from patients with myeloid leukemia and myelodysplasia to the costimulating effects of steel factor in vitro.
    Maze R; Horie M; Hendrie P; Vadhan-Raj S; Tricot G; Gordon M; Nemunaitis J; Ashman LK; Broxmeyer HE
    Exp Hematol; 1993 Apr; 21(4):545-51. PubMed ID: 7681784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
    Stasi R; Pagano A; Terzoli E; Amadori S
    Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of interleukin-3, GM-CSF, and G-CSF on the growth kinetics of colony-forming cells in myelodysplastic syndromes.
    Schipperus M; Sonneveld P; Lindemans J; Hagemeijer A; Vink N; Pegels J; Abels J
    Leukemia; 1990 Apr; 4(4):267-72. PubMed ID: 1694940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.